News

and Press

Sign up now for the latest IR news, and updates on ongoing developments at Avicanna Inc:

Avicanna Inc. to Host Second Quarter 2020 Investor Conference Call
Avicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph
Avicanna Announces Participation in a Medical Cannabis Real-World Evidence (MC-RWE) Clinical Study Led by the University Health Network in Partnership with Medical Cannabis by Shoppers™ Inc. using its Rho Phyto™ Advanced Medical Cannabis Formulary of Products
Avicanna Announces Co-development of a Cannabinoid-based Formulation for Treatment of COVID-19 related Lung Inflammation with Support from the Mitacs Accelerate Program
Avicanna to Host Virtual Symposium Titled “Medical Cannabis 2.0” on July 21st, 2020 in Partnership with Medical Cannabis By Shoppers™ in Anticipation of the Launch of its Rho Phyto™ Product Line
Avicanna Completes First Ever Export of Feminized Hemp Seeds For Cultivation Use to the United States and Closes the Initial Sale
Avicanna Successfully Registers the First Group of its Pura Earth™ CBD-Based Derma-Cosmetic Product Line in the European Union in Preparation for its Commercialization
Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update
Avicanna Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with World-Class Canadian Manufacturer MediPharm Labs
Avicanna Receives Government Support and Approval for First Ever Export of Hemp Seeds From Colombia
Avicanna Closes Non-Brokered Private Placement with Group of Strategic Investors and Announces Warrant Re-Pricing
Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update